O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+4.94%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$8.01B
AUM Growth
+$8.01B
(+1.6%)
Cap. Flow
-$10.7B
Cap. Flow
% of AUM
-133.53%
Top 10 Holdings %
Top 10 Hldgs %
34.11%
Holding
150
New
16
Increased
29
Reduced
32
Closed
15
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$189M |
| 2 |
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
|
$154M |
| 3 |
Tenet Healthcare
THC
|
$102M |
| 4 |
Merck
MRK
|
$90.6M |
| 5 |
DaVita
DVA
|
$71.4M |
Top Sells
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
$10.7B |
| 2 |
Eli Lilly
LLY
|
$193M |
| 3 |
Elevance Health
ELV
|
$148M |
| 4 |
Amgen
AMGN
|
$145M |
| 5 |
Cigna
CI
|
$130M |
Sector Composition
| 1 | Healthcare | 95.15% |
| 2 | Financials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $364M | 4.52% | 3,268,275 +388,700 | +13% | +$43.3M |
|
2
Regeneron Pharmaceuticals
REGN
$61.5B
| $332M | 4.11% | 962,900 +108,300 | +13% | +$37.3M |
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $302M | 3.75% | 1,854,600 +113,300 | +7% | +$18.5M |
|
|
4
Merck
MRK
$210B
| $288M | 3.57% | 5,288,200 +1,662,800 | +46% | +$90.6M |
|
5
Biogen
BIIB
$19.4B
| $285M | 3.53% | 1,040,400 -190,300 | -15% | -$52.1M |
|
6
Boston Scientific
BSX
$156B
| $284M | 3.52% | 10,377,795 -8,805 | -0.1% | -$241K |
|
|
CELG
7
DELISTED
Celgene Corp
CELG
| $235M | 2.91% | 2,634,250 -428,600 | -14% | -$38.2M |
|
|
8
Bristol-Myers Squibb
BMY
$96B
| $232M | 2.88% | 3,675,300 +2,987,300 | +434% | +$189M |
|
9
Ascendis Pharma
ASND
$11.8B
| $220M | 2.73% | 3,367,315 | – | – |
|
10
Agilent Technologies
A
$35.7B
| $190M | 2.35% | 2,836,900 +246,200 | +10% | +$16.5M |
|
11
Puma Biotechnology
PBYI
$254M
| $180M | 2.23% | 2,641,661 +457,126 | +21% | +$31.1M |
|
|
CMTA
12
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| $158M | 1.96% | 10,425,225 | – | – |
|
13
Jazz Pharmaceuticals
JAZZ
$7.75B
| $157M | 1.95% | 1,040,100 +432,200 | +71% | +$65.3M |
|
|
ARMO
14
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
| $154M | 1.91% | +4,118,903 | New | +$154M |
|
15
Alnylam Pharmaceuticals
ALNY
$58.5B
| $151M | 1.87% | 1,265,966 +324,366 | +34% | +$38.6M |
|
16
AbbVie
ABBV
$372B
| $145M | 1.79% | 1,527,500 +476,900 | +45% | +$45.1M |
|
17
Edwards Lifesciences
EW
$47.8B
| $143M | 1.77% | 1,024,600 -99,500 | -9% | -$13.9M |
|
|
WMGI
18
DELISTED
Wright Medical Group Inc
WMGI
| $136M | 1.69% | 6,852,068 | – | – |
|
|
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
| $123M | 1.53% | 2,330,870 +359,200 | +18% | +$19M |
|
|
AGN
20
DELISTED
Allergan plc
AGN
| $117M | 1.45% | 693,605 +406,315 | +141% | +$68.4M |
|
|
NVRO
21
DELISTED
NEVRO CORP.
NVRO
| $109M | 1.35% | 1,260,091 +362,300 | +40% | +$31.4M |
|
|
LOXO
22
DELISTED
Loxo Oncology, Inc
LOXO
| $109M | 1.35% | 941,000 -93,159,036 | -99% | -$10.7B |
|
23
Amicus Therapeutics
FOLD
$2.34B
| $106M | 1.32% | 7,072,500 +1,500,000 | +27% | +$22.6M |
|
|
BOLD
24
DELISTED
Audentes Therapeutics, Inc
BOLD
| $106M | 1.31% | 3,522,100 -607,538 | -15% | -$18.3M |
|
|
25
DaVita
DVA
$9.85B
| $103M | 1.28% | 1,559,600 +1,082,200 | +227% | +$71.4M |
|